Oncology News | pharmaphorum

News

Astellas nabs lead in claudin 18.2 after positive stomach ca...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or gastroesopha

News

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

ImmunoGen, Inc.

News

Roche deepens ties with Jnana with a second licensing deal

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-rangin

News

Lantheus on POINT in radio-oncology with $2bn licensing deal

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.

News

GSK hits another oncology hurdle as Zejula use is limited ag...

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patient

News

AZ claims another Imjudo approval, in big first-line NSCLC m...

Just a couple of weeks after finally getting its first FDA approval for CTLA4 inhibitor Imjudo for advanced liver cancer, AstraZeneca has picked up another – and in a much larger patient po

Astellas nabs lead in claudin 18.2 after positive stomach ca...

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

Roche deepens ties with Jnana with a second licensing deal

Lantheus on POINT in radio-oncology with $2bn licensing deal

GSK hits another oncology hurdle as Zejula use is limited ag...

AZ claims another Imjudo approval, in big first-line NSCLC m...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks